Case Number 9634
Request Date 15/09/2023
Completion Date 02/10/2023

 

Details of the Request

1. How many of the following intra-vitreal injections / implants has your trust administered in the four-month period from May to August 2023:

  • Aflibercept
  • Bevacizumab - Avastin
  • Bevacizumab - Biosimilar
  • Brolucizumab
  • Dexamethasone
  • Faricimab
  • Fluocinolone acetonide
  • Ranibizumab - Lucentis (pre-filled syringes)
  • Ranibizumab - Lucentis (vials)
  • Ranibizumab - Ongavia

 

2. Please provide the number of injections / implants by eye condition for the four-month period from May to August 2023:

 

Details of the Response

1. How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from May to August 2023:

  • Aflibercept = 1596
  • Bevacizumab - Avastin = 76
  • Bevacizumab - Biosimilar = 0
  • Brolucizumab = 0
  • Dexamethasone = 75
  • Faricimab = 151
  • Fluocinolone acetonide = 0
  • Ranibizumab - Lucentis (pre-filled syringes) = 704
  • Ranibizumab - Lucentis (vials) = 0
  • Ranibizumab - Ongavia = 0

 

2. Please provide the number of injections/implants by eye condition for the four-month period from May to August 2023:

Number of Injections / Implants: May - August 2023:

Treatment Wet Age-Related Macular Degeneration (wAMD) Diabetic Macular Oedema (DMO) Retinal Vein Occlusion (RVO) *
Aflibercept 904 200 168
Bevacizumab 11 0 0
Dexamethasone 0 0 6
Faricimab 144 58 0
Ranibizumab - Lucentis 421 118 29
Ranibizumab - Ongavia 0 0 0

 

* This response includes both C-RVO and B-RVO.

 

 

Protecting Your Online Privacy
Protecting Your Online Privacy

This Ashford and St Peter's website uses cookies to track visitor numbers. Find out more in our Cookies Policy and Privacy Policy. You can also read our Accessibility Statement and Privacy Notice for your information.